European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma
Go back to European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 55.65 +0.95 (1.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.70 | 52 Week High | $77.12 | |||
| Open | $55.39 | 52 Week Low | $49.03 | |||
| Day High | $55.69 | P/E | 36.14 | |||
| Day Low | $54.96 | EPS | $1.54 | |||
| Volume | 3,356,394 | |||||
